I read that article out today - found in the summary section - and learned something I didn't know. TD is currently controlled by benzodiazapines - xanax and the like - and ever-increasing doses have to be used. That is absolutely horrible. Benzos eventually turn into a total nightmare for many people using them long term - even under the strictest supervision. I've been through it and it's awful...they seem benign at first, but when you stop you can really be in trouble. It takes a long to get over them, and it's not pretty. This makes me feel even better about being invested in NBIX - Ingrezza is a major improvement for people already suffering. I started out in biotech by investing in Gilead, and pricing controversy aside, I was proud to be investing in a company eradicating a miserable disease. This is what makes biotech great.
May has been a bad week for biotech, today is particularly atrocious due to politics...and we're still flirting around our 52-week high. Tourette's data is positive. I have no doubt.
Perhaps a short-term pull back is more likely before the next rally on NBIX? google aw-esomeSTOCKS - they offer pretty good trade alerrts. you dont have to trade their tickers but it definetly helps you recognize possible patterns for stocks you're trading.
How much will it pop if TS pediatric data is positive? Glta
King of Kings
Wow, drop 8% after hour.
Politics effect, staying long, all the good news still ahead.
H.C. Wainwright issues a 130 PT target for NBIX. These analyst PTs have to be taken with a grains of salt, but I'm feeling really good about NBIX right now...and about the Tourette's data coming soon.
Which date will they announce the pediatric results??
Tree shaking before earnings
still short, still covering at $40.
I've owned NBIX for years, a sizable position and looks like I'll finally be rewarded. However HC Wainwrights ridiculous PT of $100 then $130 is not to be taken seriously under any assumptions. Besides underwriting NBIX's latest convertible offering.. which certainly makes them less objective, look at their home page and then view their underwriting offerings. (Transactions) Majority of them are "whose who" of struggling to survive companies.. NWBO, AEZS, Celsion, CYtrx and others. Lots of sub $1 offerings. On a positive note many other analysts have had a strong buy recommendation with realistic PT of $65-$85 which still represent awesome potential. Other drug approvals in their pipeline along with takeover interest would be needed to see those levels though.
I'm counting on NBIX to redeem this totally #$%$ month. Release the data!!!!
King of Kings
Is it time to load up? Now that INGREZZA has been launch.
Anything market moving potentially being announced on today's call?
King of Kings
ouch it's taking a dive.
Cool your jets people!!! we have a long way to go and it will definitely be worth the wait! Don't miss out when news is announced!!!
Like this stock (liked it even more at the price I bought it at before the approval)
Still a cracking price, strong pipeline potential (not to mention the already approved deug/application), and a strong takeover target too.
All in all, still a great deal of room for upside!
As a shareholder I want my companies to do well financially and thus reward those that have invested money. However, the indication that Ingrezza may cost as much as $10,000 per month is obscene. I intend to call and write to the company expressing my disappointment with such a ridiculous amount. Greed is not always the best road to travel.
This refuses to go over 54. When do we expect to see some decent volume on this stock?
128000 a year!!! this won't look good to the public.